CY1122601T1 - Αναστολεις gsk3 και μεθοδοι χρησης αυτων - Google Patents

Αναστολεις gsk3 και μεθοδοι χρησης αυτων

Info

Publication number
CY1122601T1
CY1122601T1 CY20191100268T CY191100268T CY1122601T1 CY 1122601 T1 CY1122601 T1 CY 1122601T1 CY 20191100268 T CY20191100268 T CY 20191100268T CY 191100268 T CY191100268 T CY 191100268T CY 1122601 T1 CY1122601 T1 CY 1122601T1
Authority
CY
Cyprus
Prior art keywords
present
methods
compounds
kinases
gsk3 inhibitors
Prior art date
Application number
CY20191100268T
Other languages
Greek (el)
English (en)
Inventor
Florence Fevrier WAGNER
Jennifer Q. PAN
Sivaraman Dandapani
Andrew Germain
Edward Holson
Benito Munoz
Partha P. NAG
Michel Weiwer
Michael C. Lewis
Stephen J. Haggarty
Joshua A. BISHOP
Kimberly Stegmaier
Versha BANERJI
Original Assignee
The Broad Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Broad Institute, Inc. filed Critical The Broad Institute, Inc.
Publication of CY1122601T1 publication Critical patent/CY1122601T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CY20191100268T 2012-10-12 2019-03-05 Αναστολεις gsk3 και μεθοδοι χρησης αυτων CY1122601T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713314P 2012-10-12 2012-10-12
US201361779394P 2013-03-13 2013-03-13
PCT/US2013/064716 WO2014059383A1 (en) 2012-10-12 2013-10-11 Gsk3 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1122601T1 true CY1122601T1 (el) 2021-03-12

Family

ID=49474737

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100268T CY1122601T1 (el) 2012-10-12 2019-03-05 Αναστολεις gsk3 και μεθοδοι χρησης αυτων

Country Status (16)

Country Link
US (4) US9096594B2 (cg-RX-API-DMAC7.html)
EP (1) EP2909204B1 (cg-RX-API-DMAC7.html)
JP (2) JP6321662B2 (cg-RX-API-DMAC7.html)
CA (1) CA2887701C (cg-RX-API-DMAC7.html)
CY (1) CY1122601T1 (cg-RX-API-DMAC7.html)
DK (1) DK2909204T3 (cg-RX-API-DMAC7.html)
ES (1) ES2719776T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190406T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043853T2 (cg-RX-API-DMAC7.html)
LT (1) LT2909204T (cg-RX-API-DMAC7.html)
PL (1) PL2909204T3 (cg-RX-API-DMAC7.html)
PT (1) PT2909204T (cg-RX-API-DMAC7.html)
RS (1) RS58700B1 (cg-RX-API-DMAC7.html)
SI (1) SI2909204T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900136T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014059383A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887701C (en) 2012-10-12 2020-12-15 The Broad Institute, Inc. Gsk3 inhibitors and methods of use thereof
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
JP6773645B2 (ja) 2014-09-03 2020-10-21 ザ ブリガム アンド ウィミンズ ホスピタル，インコーポレイテッド 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法
WO2016061344A1 (en) * 2014-10-15 2016-04-21 Mirx Pharmaceuticals Llc Gsk3 inhibitors and their uses
WO2017120543A1 (en) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3606528B1 (en) 2017-04-05 2023-10-18 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
CN110407769B (zh) * 2018-04-27 2022-11-08 复旦大学 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途
BR112020024931A2 (pt) 2018-06-05 2021-03-09 Actuate Therapeutics, Inc. Uso de um inibidor de gsk-3ss
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
US20230014430A1 (en) * 2019-11-20 2023-01-19 Washington University Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof
WO2023056463A1 (en) * 2021-09-30 2023-04-06 Trustees Of Tufts College Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome
WO2024081939A2 (en) * 2022-10-13 2024-04-18 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024259178A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Glycogen synthase kinase 3 inhibitors and uses thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722416A1 (de) 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JPH05157164A (ja) 1991-12-03 1993-06-22 Aisin Aw Co Ltd 車両用自動変速機のサーボ油圧制御装置
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
FI954775A7 (fi) 1993-04-08 1995-10-06 Du Pont Pharmaceuticals Co Uusia polysyklisiä yhdisteitä ja niiden johdoksia neurotransmittereide n vapautumista edistävinä aineina, jotka ovat käyttökelpoisia kognitii visten häiriöiden hoidossa
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP2005501800A (ja) * 2001-02-02 2005-01-20 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物およびその医薬用途
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2002100399A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
KR20060070486A (ko) * 2003-06-13 2006-06-23 젠타리스 게엠베하 포스파티딜이노시톨 3-키나제의 억제 활성을 갖는 화합물및 이의 사용 방법
PL1746097T3 (pl) * 2005-07-20 2010-06-30 Aventis Pharma Sa Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje
WO2008016123A1 (en) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
US8778986B1 (en) 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
WO2010098888A1 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
FR2945535B1 (fr) * 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
CA2887701C (en) 2012-10-12 2020-12-15 The Broad Institute, Inc. Gsk3 inhibitors and methods of use thereof
JP2014139870A (ja) * 2013-01-21 2014-07-31 Hitachi Consumer Electronics Co Ltd 照明装置およびこれを用いた映像表示装置
WO2015087996A1 (ja) 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
KR101602559B1 (ko) 2014-04-29 2016-03-10 경북대학교 산학협력단 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도
US10437707B2 (en) * 2015-03-19 2019-10-08 Teachers Insurance And Annuity Association Of America Evaluating and presenting software testing project status indicators
EP3606528B1 (en) 2017-04-05 2023-10-18 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Also Published As

Publication number Publication date
PL2909204T3 (pl) 2019-07-31
JP2015536307A (ja) 2015-12-21
LT2909204T (lt) 2019-05-10
WO2014059383A1 (en) 2014-04-17
US10137122B2 (en) 2018-11-27
RS58700B1 (sr) 2019-06-28
SMT201900136T1 (it) 2019-05-10
SI2909204T1 (sl) 2019-06-28
JP2018150302A (ja) 2018-09-27
US9096594B2 (en) 2015-08-04
US20150313890A1 (en) 2015-11-05
US20220160702A1 (en) 2022-05-26
US20140107141A1 (en) 2014-04-17
US11052080B2 (en) 2021-07-06
PT2909204T (pt) 2019-03-21
US12419885B2 (en) 2025-09-23
DK2909204T3 (en) 2019-04-01
CA2887701C (en) 2020-12-15
JP6606691B2 (ja) 2019-11-20
HRP20190406T1 (hr) 2019-05-31
US20200061050A9 (en) 2020-02-27
EP2909204A1 (en) 2015-08-26
EP2909204B1 (en) 2018-12-05
US20190175584A1 (en) 2019-06-13
HUE043853T2 (hu) 2019-09-30
JP6321662B2 (ja) 2018-05-09
ES2719776T3 (es) 2019-07-16
CA2887701A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1122712T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201690752A1 (ru) Ингибиторы g12c kras
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
EA201391106A1 (ru) Новые гетероциклические производные
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX390051B (es) Antagonistas de ep4.
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2